Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The NKG2D axis: an emerging target in cancer immunotherapy.

Lazarova M, Steinle A.

Expert Opin Ther Targets. 2019 Apr;23(4):281-294. doi: 10.1080/14728222.2019.1580693. Epub 2019 Feb 22.

PMID:
30732494
2.

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

Almeida FF, Tognarelli S, Marçais A, Kueh AJ, Friede ME, Liao Y, Willis SN, Luong K, Faure F, Mercier FE, Galluso J, Firth M, Narni-Mancinelli E, Rais B, Scadden DT, Spallotta F, Weil S, Giannattasio A, Kalensee F, Zöller T, Huntington ND, Schleicher U, Chiocchetti AG, Ugolini S, Herold MJ, Shi W, Koch J, Steinle A, Vivier E, Walzer T, Belz GT, Ullrich E.

Oncoimmunology. 2018 Aug 15;7(10):e1475875. doi: 10.1080/2162402X.2018.1475875. eCollection 2018.

3.

Cellular Mechanisms Controlling Surfacing of AICL Glycoproteins, Cognate Ligands of the Activating NK Receptor NKp80.

Neuss S, Bartel Y, Born C, Weil S, Koch J, Behrends C, Hoffmeister M, Steinle A.

J Immunol. 2018 Aug 15;201(4):1275-1286. doi: 10.4049/jimmunol.1800059. Epub 2018 Jul 6.

PMID:
29980609
4.

Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.

Zöller T, Wittenbrink M, Hoffmeister M, Steinle A.

Front Immunol. 2018 Mar 29;9:620. doi: 10.3389/fimmu.2018.00620. eCollection 2018.

5.

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma.

Kropp KN, Maurer S, Rothfelder K, Schmied BJ, Clar KL, Schmidt M, Strunz B, Kopp HG, Steinle A, Grünebach F, Rittig SM, Salih HR, Dörfel D.

Cancer Immunol Immunother. 2018 Jun;67(6):935-947. doi: 10.1007/s00262-018-2151-y. Epub 2018 Mar 19.

PMID:
29556699
6.

Pillars Article: Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA. Science. 1999. 285: 727-729.

Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T.

J Immunol. 2018 Apr 1;200(7):2231-2233. No abstract available.

7.

Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.

Maurer S, Kropp KN, Klein G, Steinle A, Haen SP, Walz JS, Hinterleitner C, Märklin M, Kopp HG, Salih HR.

Oncoimmunology. 2017 Nov 27;7(2):e1364827. doi: 10.1080/2162402X.2017.1364827. eCollection 2018.

8.

Select Clr-g Expression on Activated Dendritic Cells Facilitates Cognate Interaction with a Minor Subset of Splenic NK Cells Expressing the Inhibitory Nkrp1g Receptor.

Friede ME, Leibelt S, Dudziak D, Steinle A.

J Immunol. 2018 Feb 1;200(3):983-996. doi: 10.4049/jimmunol.1701180. Epub 2017 Dec 20.

9.

HemITAM: A single tyrosine motif that packs a punch.

Bauer B, Steinle A.

Sci Signal. 2017 Dec 5;10(508). pii: eaan3676. doi: 10.1126/scisignal.aan3676. Review.

PMID:
29208681
10.

Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors.

Koch C, Kim Y, Zöller T, Born C, Steinle A.

Front Immunol. 2017 Nov 3;8:1466. doi: 10.3389/fimmu.2017.01466. eCollection 2017.

11.

NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.

Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polić B, Weller M, Roth P.

Clin Cancer Res. 2018 Feb 15;24(4):882-895. doi: 10.1158/1078-0432.CCR-17-1766. Epub 2017 Nov 21.

12.

Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.

Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, Müller-Runte A, Lampe K, Beutner D, Quaas A, Schubert R, Herrmann E, Steinle A, Koehl U, Walter L, von Bergwelt-Baildon MS, Koch J.

Front Immunol. 2017 Apr 10;8:387. doi: 10.3389/fimmu.2017.00387. eCollection 2017.

13.

The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells.

Fischer K, Tognarelli S, Roesler S, Boedicker C, Schubert R, Steinle A, Klingebiel T, Bader P, Fulda S, Ullrich E.

Front Immunol. 2017 Mar 7;8:202. doi: 10.3389/fimmu.2017.00202. eCollection 2017.

14.

The Activating C-type Lectin-like Receptor NKp65 Signals through a Hemi-immunoreceptor Tyrosine-based Activation Motif (hemITAM) and Spleen Tyrosine Kinase (Syk).

Bauer B, Wotapek T, Zöller T, Rutkowski E, Steinle A.

J Biol Chem. 2017 Feb 24;292(8):3213-3223. doi: 10.1074/jbc.M116.759977. Epub 2017 Jan 12.

15.

Clr-a: A Novel Immune-Related C-Type Lectin-like Molecule Exclusively Expressed by Mouse Gut Epithelium.

Rutkowski E, Leibelt S, Born C, Friede ME, Bauer S, Weil S, Koch J, Steinle A.

J Immunol. 2017 Jan 15;198(2):916-926. doi: 10.4049/jimmunol.1600666. Epub 2016 Dec 12.

16.

The Stalk Domain of NKp30 Contributes to Ligand Binding and Signaling of a Preassembled NKp30-CD3ζ Complex.

Memmer S, Weil S, Beyer S, Zöller T, Peters E, Hartmann J, Steinle A, Koch J.

J Biol Chem. 2016 Dec 2;291(49):25427-25438. Epub 2016 Oct 17.

17.

Human hematopoietic CD34+ progenitor cells induce natural killer cell alloresponses via NKG2D activation.

Ulbar F, Nicolini B, Chirumbolo G, Tolomelli G, Steinle A, Rondelli D, Arpinati M.

Exp Hematol. 2016 Jan;44(1):14-23.e1. doi: 10.1016/j.exphem.2015.10.001. Epub 2015 Oct 23.

PMID:
26477527
18.

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.

Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EH, Cerwenka A, Steinle A, Koehl U, Koch J.

BMC Cancer. 2015 May 3;15:351. doi: 10.1186/s12885-015-1321-y.

19.

Immunology. MULT1plying cancer immunity.

Steinle A, Cerwenka A.

Science. 2015 Apr 3;348(6230):45-6. doi: 10.1126/science.aaa9842. No abstract available.

PMID:
25838370
21.

MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Codo P, Weller M, Meister G, Szabo E, Steinle A, Wolter M, Reifenberger G, Roth P.

Oncotarget. 2014 Sep 15;5(17):7651-62.

22.

Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.

Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, Grosse-Hovest L, Salih HR.

J Immunol. 2014 Oct 15;193(8):4261-72. doi: 10.4049/jimmunol.1400872. Epub 2014 Sep 12.

23.

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.

Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, Steinle A, Jung G, Kübler A, André MC, Grosse-Hovest L, Salih HR.

Int J Cancer. 2015 Mar 1;136(5):1073-84. doi: 10.1002/ijc.29083. Epub 2014 Jul 28.

24.

Dedicated immunosensing of the mouse intestinal epithelium facilitated by a pair of genetically coupled lectin-like receptors.

Leibelt S, Friede ME, Rohe C, Gütle D, Rutkowski E, Weigert A, Kveberg L, Vaage JT, Hornef MW, Steinle A.

Mucosal Immunol. 2015 Mar;8(2):232-42. doi: 10.1038/mi.2014.60. Epub 2014 Jul 2.

PMID:
24985083
25.

Altered microRNA expression after infection with human cytomegalovirus leads to TIMP3 downregulation and increased shedding of metalloprotease substrates, including MICA.

Esteso G, Luzón E, Sarmiento E, Gómez-Caro R, Steinle A, Murphy G, Carbone J, Valés-Gómez M, Reyburn HT.

J Immunol. 2014 Aug 1;193(3):1344-52. doi: 10.4049/jimmunol.1303441. Epub 2014 Jun 27.

26.

Transferrin' activation: bonding with transferrin receptors tunes KLRG1 function.

Steinle A.

Eur J Immunol. 2014 Jun;44(6):1600-3. doi: 10.1002/eji.201444670. Epub 2014 May 7.

27.

New prospects on the NKG2D/NKG2DL system for oncology.

Ullrich E, Koch J, Cerwenka A, Steinle A.

Oncoimmunology. 2013 Oct 1;2(10):e26097. Epub 2013 Oct 25. Review.

28.

A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Wolpert F, Tritschler I, Steinle A, Weller M, Eisele G.

Neuro Oncol. 2014 Mar;16(3):382-91. doi: 10.1093/neuonc/not232. Epub 2013 Dec 9.

29.
30.

Genetically coupled receptor-ligand pair NKp80-AICL enables autonomous control of human NK cell responses.

Klimosch SN, Bartel Y, Wiemann S, Steinle A.

Blood. 2013 Oct 3;122(14):2380-9. doi: 10.1182/blood-2013-01-479790. Epub 2013 Aug 8.

31.

BACL is a novel brain-associated, non-NKC-encoded mammalian C-type lectin-like receptor of the CLEC2 family.

Lysenko O, Schulte D, Mittelbronn M, Steinle A.

PLoS One. 2013 Jun 11;8(6):e65345. doi: 10.1371/journal.pone.0065345. Print 2013.

33.

Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.

Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH, Kabelitz D.

Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18.

34.

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection.

Koch J, Steinle A, Watzl C, Mandelboim O.

Trends Immunol. 2013 Apr;34(4):182-91. doi: 10.1016/j.it.2013.01.003. Epub 2013 Feb 13. Review.

PMID:
23414611
35.

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR.

J Immunol. 2012 Aug 1;189(3):1360-71. doi: 10.4049/jimmunol.1200796. Epub 2012 Jun 22.

36.

Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.

Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, Schadendorf D, Paschen A.

Cancer Res. 2012 Jan 15;72(2):460-71. doi: 10.1158/0008-5472.CAN-11-1977. Epub 2011 Nov 18.

37.

Natural killer (NK) cells: an important role in the immune system’s defense against viral infections. Introduction.

Diefenbach A, Steinle A.

Cell Mol Life Sci. 2011 Nov;68(21):3453-5. doi: 10.1007/s00018-011-0795-2. Epub 2011 Sep 1. No abstract available.

PMID:
21881868
38.

The polymorphic HCMV glycoprotein UL20 is targeted for lysosomal degradation by multiple cytoplasmic dileucine motifs.

Jelcic I, Reichel J, Schlude C, Treutler E, Sinzger C, Steinle A.

Traffic. 2011 Oct;12(10):1444-56. doi: 10.1111/j.1600-0854.2011.01236.x. Epub 2011 Jul 12.

39.

CD155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro.

Pfeiffer M, Seitz G, Ruck P, Mueller C, Steinle A, Lang P, Handgretinger R, Fuchs J, Warmann S.

Front Biosci (Elite Ed). 2011 Jun 1;3:1456-66.

PMID:
21622149
40.

Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.

André MC, Sigurdardottir D, Kuttruff S, Pömmerl B, Handgretinger R, Rammensee HG, Steinle A.

Int J Cancer. 2012 Oct 1;131(7):1601-10. doi: 10.1002/ijc.26191. Epub 2011 Aug 1.

41.

Vis-à-vis in the NKC: genetically linked natural killer cell receptor/ligand pairs in the natural killer gene complex (NKC).

Vogler I, Steinle A.

J Innate Immun. 2011;3(3):227-35. doi: 10.1159/000324112. Epub 2011 Mar 22. Review.

42.

Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity.

Dennehy KM, Klimosch SN, Steinle A.

J Immunol. 2011 Jan 15;186(2):657-61. doi: 10.4049/jimmunol.0904117. Epub 2010 Dec 13.

43.

Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes.

Spreu J, Kuttruff S, Stejfova V, Dennehy KM, Schittek B, Steinle A.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5100-5. doi: 10.1073/pnas.0913108107. Epub 2010 Mar 1.

44.

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M.

Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233.

45.

Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.

Müller S, Zocher G, Steinle A, Stehle T.

PLoS Pathog. 2010 Jan 15;6(1):e1000723. doi: 10.1371/journal.ppat.1000723.

46.

Establishment of cyanophycin biosynthesis in Pichia pastoris and optimization by use of engineered cyanophycin synthetases.

Steinle A, Witthoff S, Krause JP, Steinbüchel A.

Appl Environ Microbiol. 2010 Feb;76(4):1062-70. doi: 10.1128/AEM.01659-09. Epub 2009 Dec 28.

47.

Conserved amino acids within the adenovirus 2 E3/19K protein differentially affect downregulation of MHC class I and MICA/B proteins.

Sester M, Koebernick K, Owen D, Ao M, Bromberg Y, May E, Stock E, Andrews L, Groh V, Spies T, Steinle A, Menz B, Burgert HG.

J Immunol. 2010 Jan 1;184(1):255-67. doi: 10.4049/jimmunol.0902343. Epub 2009 Nov 30.

48.

Establishment of a simple and effective isolation method for cyanophycin from recombinant Saccharomyces cerevisiae.

Steinle A, Steinbüchel A.

Appl Microbiol Biotechnol. 2010 Feb;85(5):1393-9. doi: 10.1007/s00253-009-2213-3. Epub 2009 Sep 2.

PMID:
19727702
49.

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S.

Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11.

50.

Establishment of a novel anabolism-based addiction system with an artificially introduced mevalonate pathway: complete stabilization of plasmids as universal application in white biotechnology.

Kroll J, Steinle A, Reichelt R, Ewering C, Steinbüchel A.

Metab Eng. 2009 May;11(3):168-77. doi: 10.1016/j.ymben.2009.01.007. Epub 2009 Feb 5.

PMID:
19558962

Supplemental Content

Loading ...
Support Center